Health Systems Advocacy Partnership stands for mutual learning

The Health Systems Advocacy Partnership was launched in Uganda during the project kickoff session in Kampala on 18 March 2016. The strategic partnership consists of Amref Flying Doctors, African Centre for Global Health and Social Transformation (Achest), Health Action International and Wemos, and is financed by the Dutch Ministry of Foreign Affairs, the fifth partner.

The five-year partnership aims at capacity building, lobby and advocacy on sexual and reproductive health and rights (SRHR) in and for Kenia, Uganda and Zambia. At a later stage, the project will possibly be extended to a number of other African countries. The partnership works not only in the regional and national scope but takes also the global context into account.


In her speech at the launch, Dr. Jane Ruth Aceng, DG Ministry of Health, called the sexual and reproductive health and rights ‘a highest priority’ to the Ugandan government. ‘The ministry is heavily indebted to civil society organizations and their contribution to these rights.’ Dr. Francis Omaswa, director of Achest, had a clear vision of the partnership: ‘In the next five years, we will work together and create a strong network that helps strengthen health systems.’


Within the partnership, Wemos concentrates on Human Resources for Health, Governance and Financing. Mutual learning stands central to all three topics. As Anke Tijtsma, former director of Wemos, said during the kickoff: ‘We are here to learn from each other, to share our knowledge and to advocate for strong health systems in Africa. As a lobby and advocacy organization, Wemos hopes to bring forth the experiences and challenges from the countries we are working with at the Dutch government and the European Union. This will help them take their role in strengthening sexual and reproductive health and rights in Africa.’

Recent News items

Ella Weggen Wemos Kassa BNNVARA

Abuse of orphan designation leads to exorbitant drug price


Pharmaceutical company Lupin Europe is aiming to bring an existing medicine for a rare muscle disease on the market under a new name and at a much higher price. The Dutch public television programme ‘Kassa’, with more than one million viewers, reported this on November 2nd, showing how this pharmaceutical company uses public research to increase its profit margins. “This is unjustifiable and even condemnable,” says Wemos’ global health advocate Ella Weggen in the programme.

Continue reading



With prices of medicines skyrocketing under the current system of medicine development, the shortcomings of this R&D model are increasingly proving their right. Contributing to the search for possible alternative innovation mechanisms, Wemos, Health Action International and the University of Utrecht brought together representatives of government and academia on the 5th of November, with the event: LICENSING AND PUBLIC GENERATED KNOWLEDGE: SEEKING A SOCIALLY SUSTAINABLE BALANCE 

Continue reading